Therapeutic Experience


PRC Clinical has significant CRO experience in conducting clinical studies in a wide range of therapeutic areas. Our team is experienced on phase I-IV clinical studies in 35+ indications.

Regenerative Medicine


  • Congenital Retinal Disease
  • Macular Disease
    • Rare and/or Genetic indications
    • Pediatric and adults
    • Subretinal injection
    • Intravitreal injection
    • Adaptive optics retinal imaging
    • Age-related Macular Degeneration
  • Stem Cell
  • Gene Therapy



  • Non-Hodgkin’s Lymphoma
  • Solid Tumors
  • Glioblastoma
  • Brain/Breast/Bladder/Colon/Lung Cancer
  • Head and Neck Cancer
  • AML
  • NHL
  • Myeloma
  • Hematology


  • Chronic Pain
  • CNS Drug Delivery/Device
  • Neuropathic Pain
  • Surgical/Acute Pain


  • COPD
  • Pulmonary Arterial Hypertension (PAH)
  • Pulmonary Fibrosis
  • Lung Penetration


  • Dietary supplements
  • Food ingredients

Anti Infectives

  • Antibiotics Therapy
  • Hepatitis
  • Vaccine Therapy


  • Adrenal Disease
  • Diabetes


  • Celiac Disease
  • Gastroparesis


  • Hypertension
  • Nuclear Imaging
  • Stents
  • Valve Replacement

Autoimmune Disorders

  • Celiac Disease
  • Lupis
  • Myasthenia Gravis
  • MS

We have experience in conducting and supporting early-phase healthy subjects Phase I studies, Phase II, III, Registries, regenerative (stem cell), rare/orphan drug trials, as well as various medical devices and diagnostics studies:


  • Phase I-IV
  • Registries
  • Rare/Orphan drugs
  • Regenerative (Stem Cell)
  • Biosimilars

Medical Devices & Diagnostics

  • Non-inferiority
  • PMA
  • Pilot studies
  • CED


Proud member of The Alliance for Regenerative Medicine (ARM)

ARM-logo-smThe Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. Learn more about the ARM at Read our regenerative medicine clinical trial trends report.